ESG Report

Overview

The report presents 2024 as the baseline year for Optimapharm's first company-wide GHG inventory, covering Scope 1 and Scope 2. It reports 368 employees and 475 total staff including contractors, alongside a zero-fatality disclosure. ESG accountability rests with the Management Board, while the company has initiated work toward its first Double Materiality Assessment. The report also sets out ongoing efforts around responsible travel, hybrid work, digitalization, and renewable energy.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2024
Language: English
Pages
File size

Standards

Other

Materiality

Assessment
Basis

Assurance

Statement included

Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services